Experts in Conversation: Highlights from AD/PD and CONy 2024 with Dorota Religa and Robert Perneczky | Journey to a New Era for Alzheimer’s Disease
Released On
April 3, 2024
Expires On
November 30, 2025
Media Type
Internet
Completion Time
35 minutes
Specialty
Geriatric Medicine, Neurology, Psychiatry
Topics
Alzheimer's, Dementia
This activity is supported by an educational grant from Lilly.
Credit Available
- Physicians — 0.5 AMA PRA Category 1 Credit™
Target Audience
Global neurologists, geriatricians and geriatric psychiatrists. The program content will be suitable for gerontologists as well as nurse practitioners and physician assistants who are involved in the care of patients with AD.
Program Overview
2024 brought pivotal advances in neurodegenerative biomarkers for early Alzheimer’s detection, insights into amyloid-targeted therapies and patient selection, and new strategies for ARIA risk assessment and management.
Revisit 2024 Conference Highlights for Alzheimer’s Disease. Watch Experts in Conversation: Highlights from AD/PD and CONy 2024, featuring Dorota Religa (Sweden) and Robert Perneczky (Germany).
This program is part of the larger initiative, Journey to a New Era for Alzheimer’s Disease. Register for free to access news articles, video highlights, accredited expert discussions, concise research summaries, podcasts, and interactive quizzes to test your knowledge: https://new-era-alzheimers-disease.ime.springerhealthcare.com/.
Learning Objectives
After participating in this program, you will be able to:
- Endorse the importance of a proactive and accurate diagnosis of early-stage AD
- Evaluate the rationale and utility of current and emerging biomarkers within the current diagnostic work-up
- Identify which patients would most benefit from amyloid-targeted therapy use through the analysis of the most current data
- Appraise the current understanding around risk factors, detection methods, and management approaches for ARIA
Faculty
Dr Robert Perneczky
Professor of Translational Dementia Research, Director of the Division of Mental Health in Older Adults and Alzheimer Therapy and Research Center at Ludwig-Maximilians-University Munich and German Center for Neurodegenerative Diseases, Germany.
Robert Perneczky is a practicing psychiatrist and geriatrician. He is Professor of Translational Dementia Research and Director of the Division of Mental Health in Older Adults and Alzheimer Therapy and Research Center at Ludwig-Maximilians-University Munich and German Center for Neurodegenerative Diseases. He was previously Co-Director of the Neuroepidemiology Department at Imperial College London and was recently appointed to a professorial chair at University of Sheffield. Robert’s research focusses on dementia diagnoses, prevention, and treatment. His studies apply a range of methodologies to advance the understanding of biological and clinical processes that lead to cognitive decline and associated disability. This includes imaging, fluid biomarkers, and neuropsychological and lifestyle assessments in clinical and epidemiological contexts. Robert has a Master of Business Administration degree from Warwick Business School and his more recent research interests include the readiness of healthcare systems for increased cognitive screening and uptake of future disease-modifying dementia treatments, and the collection of real-world evidence to support research and patient care.
Munich, Germany
Professor Dorota Religa
Prof. Religa serves as a regular lecturer for bachelor’s, master’s, and postgraduate studies in geriatrics, neurology, and translational medicine, with particular emphasis on dementia, especially Alzheimer’s disease. Lectures include studies in the field of rehabilitation, nursing, dentistry, and medicine.
Prof. Religa participates in numerous scientific projects and collaborates with European and US centers dealing with neurodegenerative diseases. She is the author of over 100 publications in highly cited journals. She is on the Board of the Swedish Geriatrics Society and the Medicines Committee of the Senior Health Initiative. Prof. Religa is a member of the Academic Board at the European Geriatrics Society (EuGMS).
Since 2008, she has been actively participating in the guidelines group of the European Academy of Neurology (EAN) and has published 3 guidelines on the diagnosis, treatment, and management of dementia. Prof. Religa actively plans and regularly conducts educational workshops and oral lectures at many congresses of EAN, EuGMS, the Alzheimer’s Association International Conferences (AAIC), and the World Controversies in Neurology Congresses (CONy).
Stockholm, Sweden
Accreditation Statement
Credits Available
Completing one Expert in Conversation activity will earn you 0.5 AMA PRA Category 1 Credit™. The activity for CTAD is separated into 2 videos and you will need to watch both to earn 0.5. You can earn a total of 1.5 credits for all four activities.
In support of improving patient care, this activity has been planned and implemented by Postgraduate Institute for Medicine and Springer Healthcare IME. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
As part of the planning committee Rebecca Cox and Jules Morgan have no interests to disclose.
Credit Designation
Completing one Expert in Conversation activity will earn you 0.5 AMA PRA Category 1 Credit(s)™.
Disclosures of Conflicts of Interest
Robert Perneczky
Disclosures: Robert Perneczky has received honoraria for advisory boards and speaker engagements from Roche, EISAI, Eli Lilly, Biogen, Janssen-Cilag, Astra Zeneca, Schwabe, Grifols, Novo Nordisk and Tabuk.
Professor Dorota Religa
Disclosures: none to disclose
Instructions for Participation and Credit
There are no fees for participating and receiving CME credit for this enduring activity. To receive CME credit participants must:
- Read the CME/CE information and faculty disclosures.
- Participate in the online activity.
- Submit the evaluation form.
Your certificate will be made available for immediate download.
Course Viewing Requirements
Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above
Disclosure of Unlabeled Use
Springer Healthcare IME requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
Disclaimer
This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
Contact Information
For CE questions, please contact: [email protected].